This approach aims to specifically target the BRAF driver mutation, which is present in around 50% of malignant melanomas.105 The combination of MEK inhibition and T-VEC has shown increased melanoma tumour cell death in vitro106 and a Phase 1 trial of dabrafenib, trametinib and T-VEC is ongoing.107. The gene discussed is MAP2K7; the disease is melanoma.